Literature DB >> 8840280

Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy.

M C Langub1, N J Koszewski, H V Turner, M C Monier-Faugere, Z Geng, H H Malluche.   

Abstract

The cytokine interleukin-6 (IL-6) is a major cell regulatory factor that may play an important role in the bone remodeling of patients with renal failure. IL-6 exerts its action by binding to its receptor (IL-6R), which leads to transduction of a second messenger cascade within cells. In vitro as well as in vivo data point to IL-6 as an autocrine/paracrine factor in bone osteoclasts. Recently, bone cells from patients with Paget's disease were found to express IL-6 and IL-6R mRNA transcripts. However, in patients with renal bone disease, there is currently no in vivo evidence that osteoclasts have the capability to express mRNA for IL-6 and IL-6R. To investigate the potential expression of IL-6 and IL-6R in bone and its relationship to bone cell activity, iliac crest bone biopsies were performed in patients on chronic maintenance dialysis. Messenger RNA expression of IL-6 and IL-6R was studied using in situ hybridization histochemistry, and parameters of bone turnover were determined by bone histomorphometry. In the samples studied, mRNA expression of IL-6 and IL-6R was found in osteoclasts and bone marrow cells. Furthermore, we report the novel finding of increased IL-6R mRNA expression in osteoclasts engaged in increased bone resorption. The results of the present study suggest that the cytokine IL-6 is intricately involved in osteoclastic bone resorption and that expression of its receptor, IL-6R, in osteoclasts may parallel osteoclastic bone resorbing activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840280     DOI: 10.1038/ki.1996.343

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.

Authors:  S C Lin; T Yamate; Y Taguchi; V Z Borba; G Girasole; C A O'Brien; T Bellido; E Abe; S C Manolagas
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 2.  Bone biopsy in patients with osteoporosis.

Authors:  Hartmut H Malluche; Hanna Mawad; Marie-Claude Monier-Faugere
Journal:  Curr Osteoporos Rep       Date:  2007-12       Impact factor: 5.096

3.  Pathogenesis and histology of renal osteodystrophy.

Authors:  H H Malluche; M C Langub; M C Monier-Faugere
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 4.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture.

Authors:  B G Hory; M C Roussanne; S Rostand; A Bourdeau; T B Drüeke; J Gogusev
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

6.  Expression and cellular localization of interleukin-6 mRNA in ovariectomized rats.

Authors:  Y Tu; J Du; A Yang
Journal:  J Tongji Med Univ       Date:  2000

Review 7.  Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).

Authors:  Keith A Hruska; Eric T Choi; Imran Memon; T Keefe Davis; Suresh Mathew
Journal:  Pediatr Nephrol       Date:  2009-11-07       Impact factor: 3.714

8.  Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells.

Authors:  Kou Kayamori; Kei Sakamoto; Tomoki Nakashima; Hiroshi Takayanagi; Kei-Ichi Morita; Ken Omura; Su Tien Nguyen; Yoshio Miki; Tadahiro Iimura; Akiko Himeno; Takumi Akashi; Hisafumi Yamada-Okabe; Etsuro Ogata; Akira Yamaguchi
Journal:  Am J Pathol       Date:  2009-12-24       Impact factor: 4.307

Review 9.  The impact of inflammation on bone mass in children.

Authors:  Wai W Cheung; Jian-Ying Zhan; Kyung Hoon Paik; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2011-01-01       Impact factor: 3.714

10.  Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice.

Authors:  Lena Marie Westermann; Anke Baranowsky; Giorgia Di Lorenzo; Tatyana Danyukova; Jamie Soul; Jean-Marc Schwartz; Gretl Hendrickx; Michael Amling; Stefan Rose-John; Christoph Garbers; Thorsten Schinke; Sandra Pohl
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.